(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 9.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Veracyte's revenue in 2026 is $561,900,000.On average, 14 Wall Street analysts forecast VCYT's revenue for 2026 to be $48,565,648,412, with the lowest VCYT revenue forecast at $46,009,223,166, and the highest VCYT revenue forecast at $50,477,339,995. On average, 14 Wall Street analysts forecast VCYT's revenue for 2027 to be $54,027,394,676, with the lowest VCYT revenue forecast at $50,553,711,189, and the highest VCYT revenue forecast at $57,458,471,075.
In 2028, VCYT is forecast to generate $59,645,902,865 in revenue, with the lowest revenue forecast at $54,394,780,317 and the highest revenue forecast at $63,898,572,535.